EA202190572A1 - IMMUNOTHERAPY OF CANCER DISEASES RESTRICTED ON A * 01 PEPTIDES AND COMBINATIONS OF PEPTIDES AND RELATED METHODS - Google Patents
IMMUNOTHERAPY OF CANCER DISEASES RESTRICTED ON A * 01 PEPTIDES AND COMBINATIONS OF PEPTIDES AND RELATED METHODSInfo
- Publication number
- EA202190572A1 EA202190572A1 EA202190572A EA202190572A EA202190572A1 EA 202190572 A1 EA202190572 A1 EA 202190572A1 EA 202190572 A EA202190572 A EA 202190572A EA 202190572 A EA202190572 A EA 202190572A EA 202190572 A1 EA202190572 A1 EA 202190572A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- peptides
- cells
- present
- tumor
- immunotherapy
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 7
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 6
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 238000009169 immunotherapy Methods 0.000 title 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 abstract 2
- 108091008874 T cell receptors Proteins 0.000 abstract 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract 1
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 1
- 230000005975 antitumor immune response Effects 0.000 abstract 1
- 238000002619 cancer immunotherapy Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000001024 immunotherapeutic effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Настоящее изобретение относится к пептидам, белкам, нуклеиновым кислотам и клеткам для применения в иммунотерапевтических методах. В частности, настоящее изобретение относится к иммунотерапии рака. Настоящее изобретение относится далее к опухолеассоциированным пептидным эпитопам Т-клеток, в отдельности или в комбинации с другими опухолеассоциированными пептидами, которые могут, например, служить в качестве активных фармацевтических ингредиентов вакцинных композиций, стимулирующих противоопухолевые иммунные ответы, или стимулировать Т-клетки ex vivo с их перенесением в организм пациента. Пептиды, связанные с молекулами главного комплекса гистосовместимости (MHC), или пептиды в отдельности могут быть также мишенями антител, растворимых Т-клеточных рецепторов и других связывающих молекул.The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to cancer immunotherapy. The present invention further relates to tumor-associated peptide epitopes of T cells, alone or in combination with other tumor-associated peptides, which can, for example, serve as active pharmaceutical ingredients in vaccine compositions that stimulate anti-tumor immune responses, or stimulate T cells ex vivo with their transfer to the patient's body. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides alone, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862732863P | 2018-09-18 | 2018-09-18 | |
| PCT/EP2019/075065 WO2020058360A1 (en) | 2018-09-18 | 2019-09-18 | Immunotherapy with a*01 restricted peptides and combination of peptides against cancers and related methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202190572A1 true EA202190572A1 (en) | 2021-11-10 |
Family
ID=73042388
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202190572A EA202190572A1 (en) | 2018-09-18 | 2019-09-18 | IMMUNOTHERAPY OF CANCER DISEASES RESTRICTED ON A * 01 PEPTIDES AND COMBINATIONS OF PEPTIDES AND RELATED METHODS |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US20220002366A1 (en) |
| AR (1) | AR114737A1 (en) |
| EA (1) | EA202190572A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115843747A (en) * | 2022-12-02 | 2023-03-28 | 吉林大学 | Lama3 gene point mutation mouse model and construction method thereof |
-
2019
- 2019-09-18 AR ARP190102653A patent/AR114737A1/en unknown
- 2019-09-18 EA EA202190572A patent/EA202190572A1/en unknown
-
2021
- 2021-09-10 US US17/471,754 patent/US20220002366A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20220002366A1 (en) | 2022-01-06 |
| AR114737A1 (en) | 2020-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202091754A1 (en) | PEPTIDES AND COMBINATIONS OF PEPTIDES OF NON-CANONIC ORIGIN FOR USE IN IMMUNOTHERAPY OF DIFFERENT TYPES OF CANCER | |
| EA202191027A2 (en) | NEW PEPTIDES AND COMBINATIONS OF PEPTIDES FOR USE IN IMMUNOTHERAPY OF SEVERAL TUMORS | |
| EA201992664A2 (en) | NEW PEPTIDES AND PEPTID COMBINATIONS FOR APPLICATION IN THE IMMUNOTHERAPY OF OVARIAN CANCER AND OTHER TYPES OF CANCER | |
| EA201992416A1 (en) | PEPTIDES AND COMBINATIONS OF PEPTIDES FOR APPLICATION IN IMMUNOTHERAPY OF LEUKOSIS AND OTHER TYPES OF CANCER | |
| EA201891994A1 (en) | Uterus Cancer Treatment | |
| PH12021550205A1 (en) | Immunotherapy with b*07 restricted peptides and combination of peptides against cancers and related methods | |
| PH12021550346A1 (en) | B*44 restricted peptides for use in immunotherapy against cancers and related methods | |
| PH12021550581A1 (en) | Immunotherapy with a*01 restricted peptides and combination of peptides against cancers and related methods | |
| PH12020552013A1 (en) | A*03 restricted peptides for use in immunotherapy against cancers and related methods | |
| PH12020551958A1 (en) | Peptides for use in immunotherapy against cancers | |
| EA201991444A1 (en) | NEW PEPTIDES AND PEPTID COMBINATIONS FOR APPLICATION IN THE IMMUNOTHERAPY OF OVARIAN CANCER AND OTHER TYPES OF CANCER | |
| CR20210329A (en) | Immunotherapy with b*08 restricted peptides and combination of peptides against cancers and related methods | |
| EA202190572A1 (en) | IMMUNOTHERAPY OF CANCER DISEASES RESTRICTED ON A * 01 PEPTIDES AND COMBINATIONS OF PEPTIDES AND RELATED METHODS | |
| EA202190186A1 (en) | PEPTIDES, COMBINATIONS OF PEPTIDES AND CELL-BASED MEDICINES FOR USE IN IMMUNOTHERAPY OF BLADDER CANCER AND OTHER TYPES OF CANCER | |
| EA202190555A1 (en) | PEPTIDES RESTRICTED ON B * 44 FOR USE IN IMMUNOTHERAPY OF CANCER DISEASES AND RELATED METHODS | |
| EA202191411A1 (en) | IMMUNOTHERAPY OF CANCER DISEASES RESTRICTED ON B * 08 PEPTIDES AND COMBINATIONS OF PEPTIDES AND RELATED METHODS | |
| EA202190169A1 (en) | IMMUNOTHERAPY OF CANCER DISEASES RESTRICTED ON B * 07 PEPTIDES AND COMBINATIONS OF PEPTIDES AND RELATED METHODS | |
| EA202190130A1 (en) | PEPTIDES RESTRICTED ON A * 03 FOR USE IN IMMUNOTHERAPY OF CANCER AND RELATED METHODS | |
| EA202091988A1 (en) | PEPTIDES FOR USE IN IMMUNOTHERAPY OF CANCER | |
| EA201992417A1 (en) | PEPTIDES AND THEIR COMBINATIONS FOR THE APPLICATION OF CANCER DISEASES IN IMMUNOTHERAPY | |
| EA202190465A2 (en) | NEW PEPTIDES AND COMBINATIONS OF PEPTIDES FOR USE IN IMMUNOTHERAPY NHL AND OTHER TYPES OF CANCER | |
| EA202092502A3 (en) | NEW PEPTIDES AND COMBINATIONS OF PEPTIDES FOR USE IN IMMUNOTHERAPY OF SEVERAL TYPES OF CANCER | |
| EA202190241A1 (en) | NEW PEPTIDES AND COMBINATIONS OF PEPTIDES FOR USE IN IMMUNOTHERAPY OF CLL AND OTHER TYPES OF CANCER | |
| EA202190897A2 (en) | NEW PEPTIDES AND COMBINATIONS OF PEPTIDES FOR USE IN IMMUNOTHERAPY OF PANCREAS CANCER AND OTHER TYPES OF CANCER | |
| EA202191013A3 (en) | NEW PEPTIDES AND COMBINATIONS OF PEPTIDES FOR USE IN IMMUNOTHERAPY AND METHODS FOR OBTAINING FRAMEWORK FOR USE IN TREATMENT OF PANCREAS CANCER AND OTHER TYPES OF CANCER |